Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
Six-month data from Phase 2 STARLIGHT trial expected in H1 2023DALLAS, Sept. 13, 2022 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal dege ...
Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision
DALLAS, Feb. 7, 2022 -- Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b cli ...
